Demand for expertise from contract development and manufacturing organizations (CDMOs) is soaring, with the global market predicted to reach $44.17 billion during 2020-2024. With small molecules continuing to represent the majority of prescribed drugs for the foreseeable future, this is the major growth driver for the CDMO market.
In this special feature, published in Drug Development & Delivery in June 2020 (Vol 20 No 5), several leading CDMOs present case studies on how they are helping pharmaceutical companies overcome a variety of formulation and manufacturing challenges. HERMES PHARMA's Dr. Martin Koeberle (Head of Analytical Development & Stability Testing), discusses:
- Why the market for user-friendly oral dosage forms will continue to grow
- Why taste masking is critical to the acceptance of many orally administered products, especially those with a long residence time in the mouth
- How HERMES PHARMA developed a new formulation for a customer who wanted an additional ‘on-the-go’ oral formulation to meet consumer demand